Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee

This study has been completed.
Information provided by (Responsible Party):
TissueGene, Inc. Identifier:
First received: October 13, 2010
Last updated: November 13, 2014
Last verified: October 2014

The purpose of this study is to see if we can safely regenerate cartilage without invasive surgery using a biologic product called TissueGene-C.

Condition Intervention Phase
Osteoarthritis, Knee
Biological: TissueGene-C
Drug: Normal Saline
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II Study to Determine the Efficacy and Safety of Allogeneic Human Chondrocytes Expressing TGF-β1 (TissueGene-C) in Patients With Grade 3 Chronic Degenerative Joint Disease of the Knee

Resource links provided by NLM:

Further study details as provided by TissueGene, Inc.:

Primary Outcome Measures:
  • Knee Symptoms, Pain and Function Determined by the International Knee Documentation Committee (IKDC) Subjective Knee Evalution [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
    Symptoms, pain and function of the knee joint will be determined and scored using the IKDC Subjective Knee Evaluation

  • Reduction in Pain as Determined by a Visual Analog Scale (VAS) [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
    Reduction in pain as measured by a 100 mm visual analog scale

Secondary Outcome Measures:
  • Knee Symptoms, Pain and Functionality as Determined by the Knee Injury and Osteoarthritis Outcome Score(KOOS) [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
    Symptoms, pain and functionality of the knee joint as determined by Knee Injury and Osteoarthritis Outcome Score (KOOS)

  • Articular Cartilage Damage in the Knee as Determined by the Lysholm Knee Score [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
    Articular cartilage damage in the knee will be measured by the Lysholm Knee Scale

  • Comparative Evaluation of Knee Magnetic Resonance Images (MRIs) [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
    Comparison of pre-procedure 3T MRI scans to those obtained at months 3, 6, and 12 following dose administration by an independent radiographic reviewer. Evaluations will be scored using Whole Organ Magnetic Resonance imaginge Score (WORMS) and Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART).

  • Pain reduction assessed by medication usage [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
    Reduction in pain as measured by a questionnaire and the incidence and dose of analgesia.

  • Anti-inflammatory Medication Usage [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
    The incidence and dose of anti-inflammatory medications

  • Knee Function as Determined by the Lower Extremity Functional Scale [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
    Assessment of knee function as determined by the Lower Extremity Functional Scale (LEFS)

  • The Incidence of Total Knee Arthroplasty [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
    Quantification of the incidence of total knee arthroplasty of the treated knee subsequent to treatment with TissueGene-C

  • The Incidence and Severity of Injection Site Reactions [ Time Frame: 2 Years ] [ Designated as safety issue: Yes ]
    The incidence and severity of observations of the administration site including swelling, irritation, immune reaction or other abnormalities

  • The Incidence and Severity of Adverse Events in Treated Patients [ Time Frame: 2 Years ] [ Designated as safety issue: Yes ]
    The incidence and severity of adverse events assessed through 730 days (24 months) after dose administration

  • Clinically Significant Changes in Hematology and Urinalysis Parameters [ Time Frame: 2 Years ] [ Designated as safety issue: Yes ]
    The changes in clinical hematology, chemistry, and urinalysis test results at each time point from dose administration through day 730 (24 months).

  • General Health as Determined by a Validated Standardized Questionnaire [ Time Frame: 2 Years ] [ Designated as safety issue: Yes ]
    A SF-36 Questionnaire will be completed by subjects every six months (Baseline Visit and 6, 12, 18, and 24 month visits)

  • International Cartilage Repair Society (ICRS) Histological Scoring of Resected Knee Tissue [ Time Frame: 2 Years ] [ Designated as safety issue: Yes ]
    For those patients undergoing a total knee arthroplasty procedure during the study period, the resected knee tissue will undergo histological analysis and scored according to the ICRS scoring system (Mainil-Varlet et al., 2003).

Enrollment: 102
Study Start Date: May 2011
Study Completion Date: October 2014
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TissueGene-C
TissueGene-C at 3 x 10e7 cells per injection (intraarticular)
Biological: TissueGene-C
Single intraarticular injection at 3 x 10e7 cells
Other Name: TG-C
Placebo Comparator: Placebo Control
Normal Saline injection
Drug: Normal Saline
Single intraarticular injection of normal saline as a placebo control
Other Names:
  • 0.9% Saline
  • Normal Saline

Detailed Description:

Protocol TGC09201 is a multi-center, double-blind, placebo-controlled, randomized study. A total of one hundred (100) adults with grade 3 chronic degenerative joint disease (DJD) of the knee joint (as determined by radiographic examination) will be enrolled into the study. TissueGene-C will be administered intra-articularly once via x-ray guidance. TissueGene-C will be administered at a dose of 3 x 10e7 cells. Patients receiving control treatment will receive a single normal saline injection.

The objectives of this study are to:

  1. Evaluate the efficacy of TissueGene-C with regard to knee functionality and symptoms of knee osteoarthritis including pain.
  2. Evaluate the safety of administration of a single intra-articular dose of TissueGene-C as evidenced by observation of the injection site for irritation or other abnormalities, the incidence and severity of adverse events, and the changes in physical examination findings and laboratory tests, including immune analyses.
  3. Evaluate the incidence and dose of analgesia and/or anti-inflammatory medication.
  4. Evaluate the regeneration of hyaline cartilage as determined by 3T magnetic resonance imaging (MRI).
  5. Evaluate distribution of hChonJb#7 cells out of the injection site.
  6. Evaluate the efficacy of TissueGene-C by evaluating the need for total knee arthroplasty after treatment

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or Female subject
  2. Age 18 to 70 years
  3. In general good health as evidenced by physical examination, normal hematology, serum chemistry, and urinalysis screening laboratory results, and a negative history of significant organ system disorders. All laboratory values must be within 20% of normal ranges.

    1. Body Mass Index (BMI) should be between '18.5 - 45.5'. The applied scale is the same for both men and women.
    2. Blood Pressure measurements - Systolic Blood Pressure should be between 90-160mm. Hg, and Diastolic Blood Pressure between 50-90mm.Hg,
  4. Patients with Grade 3 chronic osteoarthritis of the knee as determined by the Radiographic Criteria of Kellgren and Lawrence.
  5. Symptom of pain for more than four (4) consecutive months and intensity of ≥ 40 and ≤ 90 on the 100-mm scale.
  6. Patients should be cleared to use protocol specified equipment: 3T MRI.
  7. Patients providing written informed consent after the nature of the study is fully explained and understood by the patient.

Exclusion Criteria:

  1. Age 71 or older
  2. Patients with abnormal hematology, serum chemistry, or urinalysis screening laboratory results.
  3. Patients taking non-steroidal anti-inflammatory medications within 14 days of baseline visit unless washed out as per section 3.6.4 above.
  4. Patients taking steroidal anti-inflammatory medications within 2 months of baseline visit.
  5. Patients with a recent (within 1 year) history of drug abuse and/or a positive urine drug test at the time of screening.
  6. Patients receiving injections to the treated knee within 2 months prior to study entry
  7. Patients who are contraindicated for 3T MRI.
  8. Patients who are pregnant or currently breast-feeding children.
  9. Patients with systemic, rheumatic or inflammatory disease of the knee or chondrocalcinosis, hemochromatosis, inflammatory arthritis, necrosis of the femoral condyle, arthropathy of the knee associated with juxta-articular Paget's disease of the femur or tibia, ochronosis, hemophilic arthropathy, infectious arthritis, Charcot's knee joint, villonodular synovitis, synovial chondromatosis, and/or history of inflammatory arthropathy.
  10. Patients with ongoing infectious disease, including HIV and hepatitis B or C.
  11. Patients with clinically significant cardiovascular, renal, hepatic, endocrine disease, cancer, or Type I diabetes.
  12. Patients participating in a study of an experimental drug or medical device within 30 days of study entry.
  13. Patients that will be unable to comply with the requisite study follow-up and are not able to complete all of the follow-up office visits and 3T MRI exams.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01221441

United States, Florida
Advent Clinical Research
Pinellas Park, Florida, United States, 33781
United States, Maryland
Sinai Hospital of Baltimore
Baltimore, Maryland, United States, 21215
United States, Pennsylvania
Rothman Institute
Philadelphia, Pennsylvania, United States, 19107
University Orthopedics
State College, Pennsylvania, United States, 16801
United States, Virginia
Commonwealth Orthopedics
Arlington, Virginia, United States, 22205
Sponsors and Collaborators
TissueGene, Inc.
Principal Investigator: Michael A Mont, MD Sinai Hospital of Baltimore
Principal Investigator: David W Romness, MD Commonwealth Orthopedics, Virginia Hospital Center
  More Information

No publications provided

Responsible Party: TissueGene, Inc. Identifier: NCT01221441     History of Changes
Other Study ID Numbers: TGC09201
Study First Received: October 13, 2010
Last Updated: November 13, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by TissueGene, Inc.:

Additional relevant MeSH terms:
Joint Diseases
Osteoarthritis, Knee
Musculoskeletal Diseases
Rheumatic Diseases processed this record on November 24, 2014